MORE Health, Inc., and Melax Technologies, Inc., Announce Collaboration

FOSTER CITY, Calif., March 12, 2018 /PRNewswire/ -- MORE Health, a leading global healthcare IT company announced today that it has entered into a letter of intent with Houston-based Melax Technologies. MORE Health and Melax Technologies plan to collaborate on joint research and development projects in the field of artificial intelligence, medical data and health informatics.

Dr. Hua Xu, CEO of Melax Technologies and Director of the Center for Computational Biomedicine at UTHealth said, "I chose to work with MORE Health because I valued the company's team and technology, and the company was really able to help patients. We hope that through our sincere cooperation, we can help more people in the future."

There is a growing demand for professional and consistently accurate medical translation from Chinese into English. MORE Health and Dr. Xu's team endeavor to work together to enhance the communication of medical information and improve the efficiency and accuracy of medical information translation. MORE Health plans to provide data and fund the development of AI to deepen their joint research in this field.

"Efficient, accurate interpretation and translation of medical information is critical in providing our patients quality co-diagnosis and treatment planning," said Hope Lewis, CEO of MORE Health.

Ted Bukowski, MORE Health's Senior Vice President of Provider Partnerships, was present at the signing ceremony and said, "We look forward to working with Dr. Xu and his team at Melax Technologies, this collaboration speaks directly to MORE Health's commitment to continuously improving our technology and processes in providing access to the world's best healthcare."

In the near future, MORE Health will participate in the OHDSI Conference hosted by Dr. Xu in China. And the two companies will begin a joint project to develop a medical records processing system that features Chinese language input and speech recognition.


View the online article